Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dynavax Technologies Corporation
Dynavax Presents Data From Novel Universal Flu Vaccine Candidate
May 20th, 2009
Dynavax Technologies Corporation (Nasdaq:DVAX) announced the presentation of preclinical data from its novel Universal Flu vaccine at two medical conferences this week. Through the addition of highly conserved antigens, Dynavax’s Universal Flu vaccine is designed to offer protection against divergent influenza strains, increase the efficacy of standard vaccines, and potentially reduce the dose of vaccine to extend the quantity available during a pandemic. The Company currently expects to initiate a Phase 1 clinical trial for its Universal Flu vaccine in the first half of 2010. “As we see new pandemic threats emerge, we believe that our Universal Flu approach represents...
Source: Vaccine Weekly (2009-05-20)
|
